Nmda-sensitive glutamate antagonism: A human model for psychosis

Neuropsychopharmacology

Volumn 21, Issue 6, 1999, Pages S158-S169

  Lahti, Adrienne C ^a   Holcomb, Henry H ^a   Gao, Xue Min ^a   Tamminga, Carol A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Glutamate; Human model; Ketamine; NMDA; Phencyclidine

Indexed keywords

CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; OLANZAPINE; PHENCYCLIDINE; PROTEIN C FOS;

ARTICLE; AVOIDANCE BEHAVIOR; BRAIN BLOOD FLOW; CATALEPSY; DEPOLARIZATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

EID: 0032793383     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00132-3     Document Type: Article

References (77)

1. Anand A, Berman R, Ören D, Chamey DS, Krystal JH (1999): Attenuation of NMDA antagonist effects in healthy humans by larnotrigine, a drug that reduces glutamate release. Schizophr Res 36:305
2. Andreasen NC, Rezai K, Alliger RJ, Swayze VW, Flaum M, Kirchner P, Cohen G, O’Leary DS (1992): Hypofrontal-ity in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch Gen Psychiatry 49:943-958
3. Angrist BM, Gershon S (1970): The phenomenology of experimentally induced amphetamine psychosis: Pre-liminary observations. Biol Psychiatry 2:95-107
4. Anis NA, Berry SC, Burton NR, Lodge D (1983): The disso-ciative anesthetics ketamine and phencyclidine selec-tively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. Br J Pharmacol 79:5654-5675
5. Amt J (1995): Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 283:55-62
6. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger G, Hamilton S (1997): Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol-ogy 14:111-123
7. Bell DS (1965): A comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 3:701-707
8. Braff DL, Geyer MA (1990): Sensorimotor gating and schizophrenia: Human and animal model studies. Arch Gen Psychiatry 47:181-188
9. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998): Effects of NMDA antago-nism on striatal dopamine release in healthy subjects: Application of a novel PET approach. Synapse 29:142-147
10. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997): Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy vol-unteers. Am J Psychiatry 154:805-811
11. Bymaster FP, Moore NA, Nakazawa T (1999): Review of the preclinical pharmacology of olanzapine: A MARTA class antipsychotic. Psychopharmacology 2:885-911
12. Carpenter WT Jr, Buchanan RW (1994): Schizophrenia. N Engl J Med 330:681-690
13. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Tamminga CA, Wood F (1993): Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psy-chiatry 50:825-831
14. Casey DE (1996): Behavioral effects of sertindole, risperi-done, clozapine and haloperidol in Cebus monkeys. Psychopharmacology 124:134-140
15. Cook L, Catania AC (1964): Effects of drugs on avoidance and escape behavior. Fed Proc 23:818-835
16. Corbett R, Camacho F, Woods AT, Kennan LL, Fishkin RJ, Brooks K, Dunn RW (1995): Antipsychotic agents antag-onize non-competitive N-methyl-D-aspartate antago-nist-induced behaviors. Psychopharmacology 120:67-74
17. Domino EF, Luby E (1981): Abnormal mental states induced by phencyclidine as a model of schizophrenia. In Domino EF (ed), PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, MI, NPP Books, pp 401413
18. Duncan E, Madonick SH, Angrist BM, Bartlett E, Parwani A, Rotrosen JP (1997): N-methyl-d- aspartate modulation of prepulse inhibition. Am Psychiatric Assoc Annual Meeting
19. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998): Differential effects of clozapine and haloperidol on ket-amine-induced brain metabolic activation. Brain Res812:65-75
20. Ellenbroek B, Cools AR (1988): The Paw test: An animal model for neuroleptic drugs which fulfills the criteria for pharmacological isomorphism. Life Sci 42:1205-1213
21. Farber NB, Hanslick J, Kirby C, McWilliams L, Olney JW(1998): Serotonergic agents that activate 5HT2A recep-tors prevent NMDA antagonist neurotoxicity. Neuro-psychopharmacology 18:57-62
22. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC (1994): Assessing the significance of focal activa-tions using their spatial extent. Hum Brain Mapping1:210-220
23. Gao XM, Hashimoto T, Tamminga CA (1998): Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 29:14-28
24. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tam-minga CA (1999): Ionotropic glutamate receptors and NMDA subunit expression in subregions of human hip-pocampus: Effects of schizophrenia. Am J Psychiatry, in press.
25. Grace AA, Bunney BS, Moore H, Todd CL (1997): Dopa-mine-cell depolarization block as a model for the thera-peutic actions of antipsychotic drugs. TINS 20:31-37
26. Griffith JD, Cavanaugh J, Held J (1972): Dextroamphet-amine: Evaluation of psychomimetic properties in man. Arch Gen Psychiatry 26:97-100
27. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L (1995): Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 26:602-605
28. Harborne GC, Watson FL, Healy DT, Groves L (1996): The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 10:134-140
29. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
30. Jentsch JID, Roth RH (1999): The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuro-psychopharmacology 20:201-225
31. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, VanGiersbergen PLM, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996): Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100, 907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J PharmacolExpTher277:968-981
32. Kirkpatrick B, Buchanan R (1990): The neural basis of the deficit syndrome of schizophrenia. J NervMent Dis178:545-555
33. Kristensen JD, Svensson B, Gordh T Jr (1992): The NMDA-receptor antagonist CPP abolishes neurogenic ’wind-up pain’ after intrathecal administration in humans. Pain51:249-253
34. Kroeze WK, Roth BL (1998): The molecular biology of serotonin receptors: Therapeutic implications for the interface of mood and psychosis. Biol Psychiatry 44:1128-1142
35. Krystal JH, Karper LP, Bennett A, D’Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremmer JD, Bowers MB, Suckow RF, Stetson P, Heninger GR, Char-ney DS (1998): Interactive effects of subanesthetic ketamine and subhypnoticlorazepam in humans. Psy-chopharmacology 135:213-229
36. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD, Heninger GR, Bowers IMB, Charney DS(1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199-214
37. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a): Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869-872
38. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b): Sub-anesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
39. Lahti AC, Lahti RA, Tamminga CA (1996): New neurolep-ties and experimental antipsychotics: Future roles. In Breier A (ed), The New Pharmacotherapy of Schizo-phrenia. Washington, DC, American Psychiatric Press, pp 57-87
40. Lahti AC, Holcomb HH, Weiler MA, Corey PK, Zhao M, Medoff D, Tamminga CA (1997): Effects of ketamine on behavior and CBF in schizophrenia and normal indi-viduals. Biol Psychiatry 41:165-169
41. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998): Antipsychotic properties of the partial dopamine agonist 3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in schizophrenia. Biol Psychiatry 43:2-11
42. Lahti AC, Weiler MA, Parwani A, Holcomb HH, Michaelidis T, Warfel D, Tammingac A (1999): Blockade of ket-amine-induced psychosis with olanzapine. Schizophr Res 36:310
43. LaPorte DJ, Lahti AC, Koffel B, Tamminga CA (1996): Absence of ketamine effects on memory and other cog-nitive functions in schizophrenic patients. J Psychiatr Res 30:321-330
44. Leysen JE, Janssen PM, Megens AA, Schotte A (1994): Ris-peridone: A novel antipsychotic with balanced seroto-nin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55:5-12
45. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackow-iak RS (1992): Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160:179-186
46. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959): Study of a new schizophrenomimetic drug: sere-nyl. Arch Neurol Psychiatry 71:363-369
47. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997a): Clozapine blunts N-methyl-D-Aspar-tate antagonist-induced psychosis: A study with ket-amine. Biol Psychiatry 42:664-668
48. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997b): Ketamine-free schizophren-ics. Neuropsychopharmacology 17:141-150
49. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996): NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
50. Marder SR, Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, (1993): Risperidone: Clinical development: North American results. A Canadian multicenter pla-cebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ClinNeuropharmacol 13:25-40
51. McKinney WT, Bunney WE Jr (1969): Animal model of depression. I. Review of evidence: Implications for research. Arch Gen Psychiatry 21:240-248
52. Moghaddam B, Adams BW (1998): Reversal of phencycli-dine effects by a group II metabotropic glutamate recep-tor agonist in rats. Science 281:1349-1352
53. Moghaddam B, Adams BW, Verma A, Daly D (1997): Acti-vation of glutamatergic neurotransmission by ket-amine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive dis-ruptions associated with the prefrontal cortex. J Neuro-sci 17:2921-2927
54. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melsona K, Hershey T, Craft S, Olney JW (1999a): Ket-amine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuro-psychopharmacology 20:106-118
55. Newcomer JW, Farber NB, Selke G, Melson AK, Jevtovic-Todorovic V, Olney JW (1999b): Guanabenz prevention of NMDA antagonist-induced mental symptoms in healthy humans. Schizophr Res 36:311
56. Overall JE, Gorham DR (1962): The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812
57. Pearlson GD (1981): Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. John Hopkins Med J 148:25-33
58. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byme PP (1998): Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19:434-444
59. Robertson GS, Matsumura H, Fibiger HC (1994): Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharma-col ExpTher 271:1058-1066
60. Sams-Dodd F (1999): Phencyclidine in the social interaction test: An animal model of schizophrenia with face and predictive validity. Rev Neurosci 10:59-90
61. Sanger DJ (1985): The effects of clozapine on shuttle-box avoidance responding in rats: Comparisons with haloperidol and chlordiazepoxide. PharmacolBiochem Behav 23:231-236
62. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, DeLoore K, Leysen JE (1996): Risperidone compared with new and reference antipsy-chotic drugs: In vitro and in vivo receptor binding. Psy-chopharmacology 124:57-73
63. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA (1998): Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psycho-pharmacology 140:75-80
64. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990): Neuroleptic-induced vacuous chewing move-ments as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102:474-478
65. Tamminga CA, Schaffer MH (1979): Treatment of schizo-phrenia with ergot derivatives. Psychopharmacology 66:239-242
66. Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O’Donohue TL (1987): PCP-induced alterations in cerebral glucose utilization in rat brain: Blockade by metaphit, a PCP-receptor-acylating agent. Synapse 1:497-504
67. Vollenweider EX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997): Metabolic hyper-frontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). EurNeuropsy-chopharmacol 7:9-24
68. Vollenweider FX, Leenders KL (1999): A role for cortico-stri-ato-thalamic loops in model psychoses: A PET study with FDG. Schizophr Res 36:236
69. Waddington JL (1990): Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psycho-pharmacology 101:431-447
70. Weiler MA, Thaker GK, Lahti AC, Ross DE, Tamminga CA (1997): Effects of ketamine on eye tracking in normal controls. Schizophr Res 24:246
71. Weinberger DR (1995): Neurodevelopmental perspectives on schizophrenia. In Anonymous, Psychopharmacol-ogy: The Fourth Generation of Progress. New York, Raven Press, Ltd, pp 1171-1183
72. Weiss JM, Kilts CD (1995): Animal models of depression and schizophrenia. In Schatzberg AF, Nemeroff CV (eds), Textbook of Psychopharmacology. Washington, DC, American Psychiatric Press, pp 81-123
73. Weissman AD, Dam M, London EG (1987): Alterations in local cerebral glucose utilization induced by phencycli-dine. Brain Res 435:29
74. Worms P, Broekkamp CLE, Lloyd KG (1983): Behavioral effects of neuroleptics. In Coyle JT, Enna SJ (eds), Neu-roleptics: Neurochemical, Behavioral, and Clinical Perspectives. New York, Raven, pp 93-117
75. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Womiak PJ, Sebree TB, Wallin BA, Kashkin KB (1997): A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 154:782-791
76. Zukin SR, Fitz-Syage L, Nichtenhauser R, Zukin RS (1983): Specific binding of [3H]phencyclidine in rat central ner-vous tissue: Further characterization and technical con-siderations. Brain Res 258:277-284
77. Zukin SR, Zukin RS (1979): Specific [3H]phencyclidine bind-ing in rat central nervous system. ProcNatlAcadSci USA 76:5372-5376